187 related articles for article (PubMed ID: 28425029)
1. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
Goldwater R; Hussaini A; Bosch B; Nemeth P
Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
[TBL] [Abstract][Full Text] [Related]
2. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.
Hussaini A; Olszanski AJ; Stein CA; Bosch B; Nemeth P
Cancer Chemother Pharmacol; 2017 Sep; 80(3):479-486. PubMed ID: 28695267
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of reference-scaled average bioequivalence of two oral formulations of abiraterone acetate in healthy Chinese subjects
.
Li C; Ding Y; Yang D; Wang M; Hu Y; Zhang H; Zhu X; Chen G; Li X; Wu M; Liu J; Chen H; Liu C; Shen Z; Liu B
Int J Clin Pharmacol Ther; 2018 Nov; 56(11):562-570. PubMed ID: 30220293
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers.
Wang C; Hu C; Gao D; Zhao Z; Chen X; Hu X; Gong S; Li L; Zhang L
Cancer Chemother Pharmacol; 2019 Mar; 83(3):509-517. PubMed ID: 30535959
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study.
Wu ZX; Wang CJ; Shi P; Liu YP; Li T; Sun FF; Fu Y; Gao XM; Ma YP; Cao Y
Drugs R D; 2023 Jun; 23(2):121-127. PubMed ID: 37012461
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
Nirogi R; Ravula J; Benade V; Goyal VK; Pandey SK; Dogiparti D; Jayarajan P; Kalaikadhiban I; Jetta S; Palacharla VRC
Cancer Chemother Pharmacol; 2024 Mar; 93(3):253-264. PubMed ID: 38157042
[TBL] [Abstract][Full Text] [Related]
8. Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets.
Feng Z; Liu Y; Kuang Y; Yang S; Li J; Ye L; Huang J; Pei Q; Huang Y; Yang G
Drug Des Devel Ther; 2022; 16():3-12. PubMed ID: 35018094
[TBL] [Abstract][Full Text] [Related]
9. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
[TBL] [Abstract][Full Text] [Related]
10. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
[TBL] [Abstract][Full Text] [Related]
11. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP
J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139
[TBL] [Abstract][Full Text] [Related]
12. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
13. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects.
Bouhajib M; Tayab Z
Clin Drug Investig; 2019 Mar; 39(3):309-317. PubMed ID: 30671920
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.
Boleslavská T; Rychecký O; Krov M; Žvátora P; Dammer O; Beránek J; Kozlík P; Křížek T; Hořínková J; Ryšánek P; Roušarová J; Canová NK; Šíma M; Slanař O; Štěpánek F
AAPS J; 2020 Sep; 22(6):122. PubMed ID: 32978690
[TBL] [Abstract][Full Text] [Related]
16. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
18. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
19. Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.
Almeida S; Filipe A; Neves R; Pinho C; Pedroso P; Castillo A; Trabelsi F
Arzneimittelforschung; 2011; 61(1):32-9. PubMed ID: 21355444
[TBL] [Abstract][Full Text] [Related]
20. Two Phase 1, Open-Label, Single-Dose, Randomized, Crossover Studies to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered Granules of Secnidazole (2 g) in Healthy Female Volunteers Under Different Administration Conditions.
Pentikis HS; Adetoro N
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):543-553. PubMed ID: 29125715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
